Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation th
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease
08:27am, Tuesday, 05'th Mar 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that chairman of its Scientific Advisory Board Dr. Howard Weiner will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in model
Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patients
08:31am, Monday, 08'th Jan 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have sh
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
09:30am, Friday, 05'th Jan 2024
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies,
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation
08:08am, Friday, 05'th Jan 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis study
08:56am, Tuesday, 19'th Dec 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and p
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
07:09am, Monday, 04'th Dec 2023
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patients
08:26am, Thursday, 30'th Nov 2023
Biotechnology firm Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it had successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigh
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
07:00am, Wednesday, 01'st Nov 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatment
07:23am, Wednesday, 18'th Oct 2023
Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA). Sign-off by the US Food & Drug Administ
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent results
01:15pm, Monday, 16'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 8% to $0.86 in midday trading on Monday after the clinical-stage biopharmaceutical company revealed six-month data that showed positive clinical imp
Tiziana Life Sciences reveals positive clinical results for MS patients treated with Foralumab
08:28am, Monday, 16'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measur
Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment data
04:05am, Monday, 16'th Oct 2023
In an exclusive interview with Thomas Warner from Proactive, Matthew Davis, the chief medical officer and chief operating officer of Tiziana Life Sciences Ltd (NASDAQ:TLSA), discussed the company's la
Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patients
08:34am, Friday, 13'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of
Tiziana Life Sciences to present MS treatment at ECTRIMS Annual Congress
09:26am, Wednesday, 11'th Oct 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Saf
